22nd July 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

Govt launched three initiatives for pharma MSMEs

In order to support MSMEs in pharma industry, the government introduced three schemes. Pharma MSMEs with a track record of success could update their technology with the help of the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS).

Reduction of supply chain constraints may alleviate Gland Pharma's discomfort

Shares of Gland Pharma hit a 52-week low of $2,180 per, dropping by nearly 6% as the session came to a close. Revenues in India decreased by 72% year over year (y-o-y) as a result of the country’s decision to shut down two production lines in order to increase productivity.

Organon and Cognizant work together to improve women's healthcare

A global women’s health company named Organon and Cognizant have entered a new multi-year deal to help Organon distribute healthcare products and manage its vital pharmaceutical supply chain.

Biological E invest Rs 1800 crore to expand vaccine output, injectables, and R&D

The manufacturer of vaccines Biological E revealed plans for growth that will cost over Rs 1,800 crore and increase employment for more than 2500 people. The expansion is largely intended to increase vaccine production as well as generic injectables and R&D.

USFDA approves Zydus' blood pressure injection

According to Zydus Lifesciences, the US health regulator has given the company permission to commercialize generic blood pressure-lowering drugs in the US market and issued the business final approval to market Norepinephrine Bitartrate Injection.

Sandoz's Supplemental Biologics License Application for biosimilar Hyrimoz approved by USFDA

FDA has accepted Sandoz’s Supplemental Biologics License Application (sBLA) for assessment of a high concentration formulation of its biosimilar Hyrimoz at a concentration of 100 mg/mL (adalimumab-adaz).

Novartis withdraws PD-1 bid for non-small cell lung cancer

Novartis and BeiGene are withdrawing their application for tislelizumab as a monotherapy for non-small cell lung cancer, just days after the FDA delayed a decision about the drug’s use in previously treated esophageal squamous cell carcinoma (ESCC).

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?